Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Preferred Stock Liabilities (2019 - 2020)

Pulmonx (LUNG) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $207.6 million as the latest value for Q3 2020.

  • On a quarterly basis, Preferred Stock Liabilities rose 1.1% to $207.6 million in Q3 2020 year-over-year; TTM through Sep 2020 was $207.6 million, a 1.1% increase, with the full-year FY2019 number at $205.3 million, up 46.11% from a year prior.
  • Preferred Stock Liabilities was $207.6 million for Q3 2020 at Pulmonx, roughly flat from $207.6 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $207.6 million in Q1 2020 to a low of $205.3 million in Q3 2019.